Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.


Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
02 2019
Historique:
received: 31 07 2018
accepted: 07 08 2018
pubmed: 20 8 2018
medline: 14 5 2020
entrez: 20 8 2018
Statut: ppublish

Résumé

The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.

Identifiants

pubmed: 30121316
pii: S0022-3549(18)30505-7
doi: 10.1016/j.xphs.2018.08.006
pii:
doi:

Substances chimiques

Immunoglobulins, Intravenous 0
Protein Aggregates 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

832-841

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Masato Kiyoshi (M)

Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.

Hiroko Shibata (H)

Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan. Electronic address: h-shibata@nihs.go.jp.

Akira Harazono (A)

Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.

Tetsuo Torisu (T)

Vaccine Operations, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan.

Takahiro Maruno (T)

U-Medico Inc., 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.

Michiko Akimaru (M)

Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan.

Yuuka Asano (Y)

Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan.

Mai Hirokawa (M)

Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan.

Keisuke Ikemoto (K)

Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan.

Yukari Itakura (Y)

Biologics and New Modalities Development, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan.

Takafumi Iwura (T)

Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan.

Aya Kikitsu (A)

Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan.

Takashi Kumagai (T)

Pharmaceutical Science and Technology Labs, Pharmaceutical Technology, Astellas Pharma Inc., 2-5-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan.

Naoki Mori (N)

Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan.

Hiroaki Murase (H)

Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan.

Hirotaka Nishimura (H)

Pharmaceutical Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan.

Atsushi Oda (A)

CMC Regulatory and Analytical R&D, Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan.

Taiichiro Ogawa (T)

CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan.

Takuma Ojima (T)

Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan.

Shinji Okabe (S)

Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan.

Shuntaro Saito (S)

Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan.

Satoshi Saitoh (S)

Pharmaceutical Technology Division, Quality Development Department, Chugai Pharma Manufacturing, 5-1, Ukima, 5-chome, Kita-ku, Tokyo 115-8543, Japan.

Hiroyuki Suetomo (H)

Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan.

Kazuhiro Takegami (K)

CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan.

Momoko Takeuchi (M)

Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan.

Hidehito Yasukawa (H)

Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan.

Susumu Uchiyama (S)

Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.

Akiko Ishii-Watabe (A)

Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.

Articles similaires

1.00
Humans Cross-Sectional Studies Telemedicine Japan Surveys and Questionnaires
Fragaria Light Plant Leaves Osmosis Stress, Physiological
Humans Out-of-Hospital Cardiac Arrest Female Male Japan

Validity of the self-reported number of teeth in independent older people in Japan.

Yoshihiro Shimazaki, Mizuki Saito, Toshiya Nonoyama et al.
1.00
Humans Japan Female Aged Self Report

Classifications MeSH